In a study performed by Haga et al., the authors demonstrated that the overexpression of c-Jun contributes to sorafenib resistance in HCC [61,62] and the modulation and phosphorylation of c-Jun could be a new therapeutic option for enhancing responsiveness to sorafenib. The gene discussed is JUN; the disease is hepatocellular carcinoma.